- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT05995353
Исследование для оценки нежелательных явлений, изменения активности заболевания и того, как рисанкизумаб, введенный внутривенно и подкожно, перемещается в организме участников педиатрического профиля с болезнью Крона от умеренной до тяжелой степени (RISE)
Фаза 3, многоцентровое исследование для оценки фармакокинетики, эффективности и безопасности рисанкизумаба с открытой индукцией, рандомизированным двойным слепым поддерживающим лечением и длительными периодами продления у детей (от 2 до < 18 лет) с Активная болезнь Крона от умеренной до тяжелой степени
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to < 18 years old who have had intolerance or inadequate response to other therapies.
Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Approximately 110 pediatric participants with CD will be enrolled at around 100 sites worldwide.
Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 3
Контакты и местонахождение
Контакты исследования
- Имя: ABBVIE CALL CENTER
- Номер телефона: 844-663-3742
- Электронная почта: abbvieclinicaltrials@abbvie.com
Места учебы
-
-
-
Brussels, Бельгия, 1020
- Рекрутинг
- Hospital Universite Enfants Reine Fabiola /ID# 255112
-
Liège, Бельгия, 4000
- Рекрутинг
- Groupe Sante CHC - Clinique du MontLegia /ID# 255620
-
-
Antwerpen
-
Edegem, Antwerpen, Бельгия, 2650
- Рекрутинг
- Uza /Id# 255114
-
-
Brussels Capital
-
Brussels, Brussels Capital, Бельгия, 1200
- Рекрутинг
- Cliniques Universitaires UCL Saint-Luc /ID# 255108
-
Jette, Brussels Capital, Бельгия, 1090
- Рекрутинг
- Universitair Ziekenhuis Brussel /ID# 255109
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Бельгия, 3000
- Рекрутинг
- Universitair Ziekenhuis Leuven /ID# 255098
-
-
-
-
-
Plovdiv, Болгария, 4002
- Рекрутинг
- UMHAT Sveti Georgi EAD /ID# 255386
-
Sofia, Болгария, 1606
- Завершенный
- Specialized Hospital For Active Treatment Of Children Diseases Prof. Ivan Mitev /ID# 255384
-
Varna, Болгария, 9009
- Рекрутинг
- UMHAT Multiprofile Hospital for Active Treatment Sveta Marina /ID# 256358
-
-
-
-
Bavaria
-
Munich, Bavaria, Германия, 80337
- Рекрутинг
- Dr. von Haunerschen Kinderspital /ID# 255577
-
-
North Rhine-Westphalia
-
Münster, North Rhine-Westphalia, Германия, 48149
- Рекрутинг
- Universitaetsklinikum Muenster /ID# 256762
-
-
-
-
Central District
-
Petah Tikva, Central District, Израиль, 4920235
- Рекрутинг
- Schneider Children's Medical Center /ID# 254950
-
-
Jerusalem
-
Jerusalem, Jerusalem, Израиль, 91031
- Рекрутинг
- Shaare Zedek Medical Center /ID# 254951
-
-
-
-
-
Madrid, Испания, 28009
- Завершенный
- Hospital Infantil Universitario Nino Jesus /ID# 255012
-
Málaga, Испания, 29011
- Рекрутинг
- Hospital Regional Universitario de Malaga /ID# 257553
-
-
A Coruna
-
Ferrol, A Coruna, Испания, 15405
- Рекрутинг
- Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 255614
-
-
-
-
-
Messina, Италия, 98125
- Рекрутинг
- Azienda Ospedaliera Universitaria Gaetano Martino /ID# 255044
-
-
Genova
-
Genoa, Genova, Италия, 16147
- Рекрутинг
- IRCCS Istituto Giannina Gaslini /ID# 255262
-
-
Napoli
-
Naples, Napoli, Италия, 80131
- Рекрутинг
- Azienda Ospedaliera Universitaria Federico II - Naples /ID# 255045
-
-
Roma
-
Rome, Roma, Италия, 00165
- Рекрутинг
- Ospedale Pediatrico Bambino Gesu /ID# 255043
-
-
-
-
Alberta
-
Calgary, Alberta, Канада, T3B 6A8
- Рекрутинг
- Alberta Children's Hospital /ID# 255357
-
Edmonton, Alberta, Канада, T6G 1C9
- Рекрутинг
- Edmonton Clinic Health Academy /ID# 255361
-
-
British Columbia
-
Vancouver, British Columbia, Канада, V6H 3V4
- Рекрутинг
- BC Children's Hospital /ID# 255359
-
-
Ontario
-
London, Ontario, Канада, N6A 5W9
- Рекрутинг
- London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 258598
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Китай, 100045
- Рекрутинг
- Beijing Children's Hospital /ID# 256081
-
Beijing, Beijing Municipality, Китай, 100191
- Рекрутинг
- Peking University Third Hospital /ID# 255876
-
Контакт:
- Site Coordinator
- Номер телефона: +86 010-82266699
-
-
Guangdong
-
Guangzhou, Guangdong, Китай, 510620
- Рекрутинг
- Guangzhou Medical University Affiliated Women and Children's Medical Center /ID# 255428
-
Guangzhou, Guangdong, Китай, 510655
- Рекрутинг
- The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 270589
-
-
Henan
-
Zhengzhou, Henan, Китай, 450018
- Рекрутинг
- Henan Children's Hospital Zhengzhou Children's Hospital /ID# 255562
-
-
Hunan
-
Changsha, Hunan, Китай, 410007
- Рекрутинг
- Hunan Children's Hospital /ID# 255610
-
-
Jiangxi
-
Nanchang, Jiangxi, Китай, 330006
- Рекрутинг
- Jiangxi Provincial Children's Hospital /ID# 255564
-
-
Liaoning
-
Shenyang, Liaoning, Китай, 110022
- Рекрутинг
- Shengjing Hospital of China Medical University /ID# 255563
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Китай, 200062
- Рекрутинг
- Children's Hospital of Shanghai /ID# 255531
-
Shanghai, Shanghai Municipality, Китай, 200065
- Рекрутинг
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 255688
-
-
-
-
North Holland
-
Amsterdam, North Holland, Нидерланды, 1105 AZ
- Рекрутинг
- Amsterdam University Medical Center /ID# 254827
-
-
-
-
Kuyavian-Pomeranian Voivodeship
-
Torun, Kuyavian-Pomeranian Voivodeship, Польша, 87-100
- Завершенный
- Gastromed Sp. z o.o /ID# 255939
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Польша, 04-730
- Рекрутинг
- Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 255938
-
-
-
-
-
Dorado, Пуэрто-Рико, 00646
- Рекрутинг
- Puerto Rico Health Institute /ID# 255071
-
San Juan, Пуэрто-Рико, 00909-1711
- Рекрутинг
- Clinical Research Puerto Rico /ID# 266479
-
-
-
-
-
Birmingham, Соединенное Королевство, B4 6NH
- Рекрутинг
- Birmingham Women's and Children's NHS Foundation Trust /ID# 255759
-
-
England
-
Sheffield, England, Соединенное Королевство, S10 2TH
- Рекрутинг
- Sheffield Children's Hospital NHS Foundation Trust /ID# 255758
-
Контакт:
- Site Coordinator
- Номер телефона: +44 114 273 0522
-
-
Greater London
-
London, Greater London, Соединенное Королевство, E1 2ES
- Рекрутинг
- Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 255757
-
-
-
-
Arizona
-
Phoenix, Arizona, Соединенные Штаты, 85016-7710
- Рекрутинг
- Phoenix Children's Hospital /ID# 255766
-
-
Arkansas
-
Little Rock, Arkansas, Соединенные Штаты, 72202
- Завершенный
- Arkansas Children's Hospital /ID# 255762
-
-
California
-
Oakland, California, Соединенные Штаты, 94609
- Рекрутинг
- UCSF Benioff Children's Hospital - Oakland /ID# 258327
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80045
- Рекрутинг
- Children's Hospital Colorado - Aurora /ID# 255764
-
-
Florida
-
Orlando, Florida, Соединенные Штаты, 32806-1141
- Рекрутинг
- Arnold Palmer Hospital for Children Center Digestive Health and Nutrition-Orland /ID# 255437
-
-
Indiana
-
Indianapolis, Indiana, Соединенные Штаты, 46202
- Рекрутинг
- Indiana University Health Riley Hospital for Children /ID# 256454
-
-
Massachusetts
-
Waltham, Massachusetts, Соединенные Штаты, 02451
- Рекрутинг
- Massachusetts General Hospital - Mass General Waltham /ID# 255767
-
-
Minnesota
-
Minneapolis, Minnesota, Соединенные Штаты, 55413-2195
- Рекрутинг
- MNGI Digestive Health, P. A. /ID# 255366
-
-
New Jersey
-
Morristown, New Jersey, Соединенные Штаты, 07960
- Рекрутинг
- Goryeb Childrens Hospital /ID# 256452
-
-
New York
-
New York, New York, Соединенные Штаты, 10029
- Рекрутинг
- Icahn School of Medicine at Mount Sinai /ID# 254880
-
-
Ohio
-
Cleveland, Ohio, Соединенные Штаты, 44195
- Рекрутинг
- Cleveland Clinic - Cleveland /ID# 256453
-
Контакт:
- Site Coordinator
- Номер телефона: 216-636-2007
-
-
-
-
-
Changhua City, Changhua County, Тайвань, 50006
- Рекрутинг
- Changhua Christian Hospital /ID# 256082
-
Taipei, Тайвань, 100
- Рекрутинг
- National Taiwan University Hospital /ID# 255679
-
-
-
-
-
Ankara, Турция (Туркие), 06560
- Рекрутинг
- Gazi University Medical Faculty /ID# 255086
-
Istanbul, Турция (Туркие), 34453
- Рекрутинг
- Sariyer Hamidiye Etfal Egitim Ve Araştirma Hastanesi /ID# 257143
-
Istanbul, Турция (Туркие), 34899
- Рекрутинг
- Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 261020
-
Kocaeli, Турция (Туркие), 41380
- Рекрутинг
- Kocaeli University Med Faculty /ID# 256922
-
-
-
-
-
Paris, Франция, 75015
- Рекрутинг
- AP-HP - Hopital Necker /ID# 255608
-
-
Centre-Val de Loire
-
Tours, Centre-Val de Loire, Франция, 37044
- Рекрутинг
- CHRU Tours - Hopital Gatien de Clocheville /ID# 255052
-
-
New Aquitaine
-
Bordeaux, New Aquitaine, Франция, 33076
- Рекрутинг
- Chu Bordeaux - Hopital Pellegrin /ID# 257060
-
-
Occitanie
-
Toulouse, Occitanie, Франция, 31059
- Рекрутинг
- CHU Toulouse - Hopital Paule de Viguier /ID# 255609
-
-
Rhone
-
Bron, Rhone, Франция, 69500
- Рекрутинг
- Hospices Civils de Lyon - Hopital Femme Mere Enfant /ID# 255443
-
-
-
-
Praha 17
-
Prague, Praha 17, Чехия, 128 00
- Завершенный
- Vseobecna Fakultni nemocnice v Praze /ID# 256096
-
-
Praha 5
-
Prague, Praha 5, Чехия, 150 06
- Завершенный
- Fakultni nemocnice Motol a Homolka /ID# 256547
-
-
-
-
-
Bern, Швейцария, 3010
- Рекрутинг
- Inselspital, Universitaetsspital Bern /ID# 255321
-
-
Canton of Zurich
-
Zurich, Canton of Zurich, Швейцария, 8032
- Рекрутинг
- Kinderspital Zurich - Eleonorenstiftung /ID# 255337
-
-
-
-
Stockholm County
-
Stockholm, Stockholm County, Швеция, 118 83
- Рекрутинг
- Sodersjukhuset /ID# 255239
-
Stockholm, Stockholm County, Швеция, 171 76
- Рекрутинг
- Astrid Lindgrens Barnsjukhus /ID# 255240
-
-
Västra Götaland County
-
Gothenburg, Västra Götaland County, Швеция, 413 46
- Рекрутинг
- Sahlgrenska Universitetssjukhuset /ID# 255236
-
Контакт:
- Site Coordinator
- Номер телефона: +46313435865
-
-
-
-
-
Daegu, Южная Корея, 41404
- Рекрутинг
- Kyungpook National University Chilgok Hospital /ID# 255817
-
-
Seoul Teugbyeolsi
-
Seoul, Seoul Teugbyeolsi, Южная Корея, 03080
- Рекрутинг
- Seoul National University Hospital /ID# 255318
-
Seoul, Seoul Teugbyeolsi, Южная Корея, 06351
- Рекрутинг
- Samsung Medical Center /ID# 255284
-
Seoul, Seoul Teugbyeolsi, Южная Корея, 03722
- Рекрутинг
- Yonsei University Health System - Severance Hospital /ID# 256976
-
-
-
-
Aichi-ken
-
Ōbu, Aichi-ken, Япония, 474-8710
- Рекрутинг
- Aichi Children's Health And Medical Center /ID# 272085
-
-
Chiba
-
Kashiwa-shi, Chiba, Япония, 277-0871
- Рекрутинг
- Tsujinaka Hospital - Kashiwanoha /ID# 268409
-
-
Fukuoka
-
Kurume-shi, Fukuoka, Япония, 830-0011
- Рекрутинг
- Kurume University Hospital /ID# 268418
-
-
Gunma
-
Maebashi, Gunma, Япония, 371-8511
- Рекрутинг
- Gunma University Hospital /ID# 270560
-
-
Kumamoto
-
Kumamoto, Kumamoto, Япония, 861-8520
- Рекрутинг
- Japanese Red Cross Kumamoto Hospital /ID# 268586
-
-
Osaka
-
Izumi-Shi, Osaka, Япония, 594-1101
- Рекрутинг
- Osaka Women's and Children's Hospital /ID# 268419
-
-
Saitama
-
Saitama-shi, Saitama, Япония, 330-8777
- Рекрутинг
- Saitama Children's Medical Center /ID# 268410
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Япония, 113-8519
- Рекрутинг
- Institute of Science Tokyo Hospital /ID# 269175
-
Fuchu-shi, Tokyo, Япония, 183-8561
- Рекрутинг
- Tokyo Metropolitan Children's Medical Center /ID# 268415
-
Setagaya City, Tokyo, Япония, 157-8535
- Рекрутинг
- National Center For Child Health And Development /ID# 268420
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Pediatric individuals, 2 to < 18 years old
- Must have moderately to severely active CD, as defined by the PCDAI score > 30 assessed at Baseline
- Must have endoscopic evidence of mucosal inflammation as documented by the SES-CD of ≥ 6 for ileocolonic or colonic disease (or SES-CD of ≥ 4 for isolated ileal disease)
- Demonstrated intolerance or inadequate response to one or more of the following categories of drugs: aminosalicylates (This drug class is not sufficient for eligibility for subjects in France, Italy, Netherlands, Spain, and Sweden), oral locally acting corticosteroids, systemic steroids (prednisone or equivalent), IMMs, and/or biologic therapies
Exclusion Criteria:
-
History of hereditary fructose intolerance (a rare genetic condition) or an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and/or other products in the same class
-
Any of the following medical disorders:
-
Current diagnosis of ulcerative colitis, indeterminate colitis, or monogenic IBD.
-
A diagnosis of CD prior to 2 years of age.
-
A diagnosis or suspected diagnosis of a primary immunodeficiency.
-
Currently known complications of CD such as:
- Active abscess (abdominal or perianal);
- Symptomatic bowel strictures;
- > 2 missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum;
- Fulminant colitis;
- Toxic megacolon;
- Or any other manifestation that might require surgery while enrolled in the study.
-
Ostomy or ileoanal pouch.
-
Diagnosis of short gut or short bowel syndrome.
-
Surgical bowel resection within the past 3 months prior to Baseline (excluding gastrointestinal surgeries which are not bowel resections such as appendectomy or ostomy closure), or a history of >3 bowel resections.
-
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Последовательное назначение
- Маскировка: Четырехместный
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: PK Cohort 1: SS3 Dose A
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Другие имена:
Subcutaneous (SC) Injection
Другие имена:
|
|
Экспериментальный: PK Cohort 1: SS3 Dose B
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Другие имена:
Subcutaneous (SC) Injection
Другие имена:
|
|
Экспериментальный: PK Cohort 2: SS1
Cohort 2 will enroll participants aged 2 to less than 6 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2. |
Intravenous (IV) Infusion
Другие имена:
Subcutaneous (SC) Injection
Другие имена:
|
|
Экспериментальный: PK Cohort 2: SS3 Dose A
Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Другие имена:
Subcutaneous (SC) Injection
Другие имена:
|
|
Экспериментальный: PK Cohort 2: SS3 Dose B
Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Другие имена:
Subcutaneous (SC) Injection
Другие имена:
|
|
Экспериментальный: Expansion Cohort 3: SS3 Dose A
Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Другие имена:
Subcutaneous (SC) Injection
Другие имена:
|
|
Экспериментальный: Expansion Cohort 3: SS3 Dose B
Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Intravenous (IV) Infusion
Другие имена:
Subcutaneous (SC) Injection
Другие имена:
|
|
Экспериментальный: PK Cohort 1: SS1
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All participants who complete SS1 are eligible to enter SS2. |
Intravenous (IV) Infusion
Другие имена:
Subcutaneous (SC) Injection
Другие имена:
|
|
Экспериментальный: PK Cohort 1: SS2 Dose A
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Другие имена:
Subcutaneous (SC) Injection
Другие имена:
|
|
Экспериментальный: PK Cohort 1: SS2 Dose B
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Другие имена:
Subcutaneous (SC) Injection
Другие имена:
|
|
Экспериментальный: PK Cohort 2: SS2 Dose A
Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Другие имена:
Subcutaneous (SC) Injection
Другие имена:
|
|
Экспериментальный: PK Cohort 2: SS2 Dose B
Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Другие имена:
Subcutaneous (SC) Injection
Другие имена:
|
|
Экспериментальный: Expansion Cohort 3: SS1
Cohort 3 will enroll participants aged 2 to less than 18 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2. |
Intravenous (IV) Infusion
Другие имена:
Subcutaneous (SC) Injection
Другие имена:
|
|
Экспериментальный: Expansion Cohort 3: SS2 Dose A
Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Другие имена:
Subcutaneous (SC) Injection
Другие имена:
|
|
Экспериментальный: Expansion Cohort 3: SS2 Dose B
Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3. |
Intravenous (IV) Infusion
Другие имена:
Subcutaneous (SC) Injection
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission
Временное ограничение: At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 64 weeks
|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per Simple Endoscopic Score for Crohn's Disease (SES-CD)
Временное ограничение: At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 64 weeks
|
|
Cohorts 1 & 2: Maximum Observed Serum Concentration (Cmax) of Risankizumab
Временное ограничение: Up to approximately Week 64
|
Cmax of risankizumab |
Up to approximately Week 64
|
|
Cohorts 1 & 2: Time to Cmax (Tmax) of Risankizumab
Временное ограничение: Up to approximately 64 weeks
|
Tmax of risankizumab |
Up to approximately 64 weeks
|
|
Cohorts 1 & 2: Area Under the Serum Concentration-Time Curve Over the Dosing Interval (AUCtau) of Risankizumab
Временное ограничение: Up to approximately 64 weeks
|
AUCtau of risankizumab |
Up to approximately 64 weeks
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Cohort 3 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
Временное ограничение: At 12 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 12 weeks
|
|
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
Временное ограничение: At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 12 weeks
|
|
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Временное ограничение: At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 12 weeks
|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Временное ограничение: At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 64 weeks
|
|
Cohort 3 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
Временное ограничение: At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit. |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving PCDAI Clinical Remission
Временное ограничение: At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per SES-CD
Временное ограничение: At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
Временное ограничение: At 12 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10. |
At 12 weeks
|
|
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
Временное ограничение: At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline). |
At 12 weeks
|
|
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Временное ограничение: At 12 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 12 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Временное ограничение: At 64 weeks
|
The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader. |
At 64 weeks
|
|
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
Временное ограничение: At 64 weeks
|
PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit. |
At 64 weeks
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: ABBVIE INC., AbbVie
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- M16-194
- 2022-502050-14-00 (Другой идентификатор: EU CT)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Сроки обмена IPD
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Критерии совместного доступа к IPD
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Совместное использование IPD Поддерживающий тип информации
- STUDY_PROTOCOL
- САП
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .